Lexeo Therapeutics (LXEO) News Today $4.88 -0.19 (-3.75%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period RBC Capital Sticks to Their Buy Rating for Lexeo Therapeutics, Inc. (LXEO)January 21 at 8:31 PM | markets.businessinsider.comLexeo Therapeutics (NASDAQ:LXEO) Given "Outperform" Rating at Royal Bank of CanadaRoyal Bank of Canada reaffirmed an "outperform" rating and issued a $24.00 price objective on shares of Lexeo Therapeutics in a research note on Tuesday.January 21 at 12:22 PM | marketbeat.comLexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Consensus Recommendation of "Buy" by BrokeragesShares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) have been given an average recommendation of "Buy" by the six analysts that are presently covering the stock, Marketbeat reports. Five equities research analysts have rated the stock with a buy rating and one has assigned a strongJanuary 17, 2025 | marketbeat.comSolid Biosciences stock jumps 11% post-market on FDA updateJanuary 7, 2025 | msn.comLexeo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 7, 2025 | globenewswire.comGeode Capital Management LLC Increases Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO)Geode Capital Management LLC increased its stake in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) by 86.5% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 553,247 shares of the company'sJanuary 5, 2025 | marketbeat.comLexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Recommendation of "Buy" from BrokeragesShares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) have been given an average rating of "Buy" by the six research firms that are presently covering the stock, Marketbeat reports. Five research analysts have rated the stock with a buy recommendation and one has given a strong buy reDecember 23, 2024 | marketbeat.comLexeo Therapeutics Appoints Dr. Kyle Rasbach as CFODecember 20, 2024 | markets.businessinsider.comLexeo Therapeutics Appoints Kyle Rasbach As CFODecember 19, 2024 | markets.businessinsider.comLexeo Therapeutics Names Kyle Rasbach Chief Financial OfficerDecember 19, 2024 | marketwatch.comLexeo Therapeutics Appoints Kyle Rasbach as Chief Financial OfficerDecember 19, 2024 | globenewswire.comLexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Sells $20,500.00 in StockDecember 13, 2024 | insidertrades.comFrazier Life Sciences Management L.P. Invests $11.31 Million in Lexeo Therapeutics, Inc. (NASDAQ:LXEO)Frazier Life Sciences Management L.P. bought a new position in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 1,250,786 shares of the company'sDecember 10, 2024 | marketbeat.comPoint72 Asset Management L.P. Acquires Shares of 370,407 Lexeo Therapeutics, Inc. (NASDAQ:LXEO)Point72 Asset Management L.P. acquired a new stake in Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 370,407 shares of the company's stock, valued at approximately $December 10, 2024 | marketbeat.comJanus Henderson Group PLC Grows Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO)Janus Henderson Group PLC raised its position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) by 18.9% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,763,195 shares of the company's stock after acquiring anDecember 7, 2024 | marketbeat.comRA Capital Management L.P. Trims Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO)RA Capital Management L.P. lessened its holdings in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) by 18.8% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 546,554 shares of the company's stocDecember 5, 2024 | marketbeat.comLexeo Therapeutics, Inc. (NASDAQ:LXEO) Shares Bought by Verition Fund Management LLCVerition Fund Management LLC grew its stake in Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) by 84.5% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 777,320 shares of the company's stock after purchasing an addDecember 2, 2024 | marketbeat.comBraidwell LP Sells 653,704 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO)Braidwell LP cut its holdings in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) by 47.3% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 728,777 shares of the company's stock after sNovember 29, 2024 | marketbeat.comEventide Asset Management LLC Reduces Holdings in Lexeo Therapeutics, Inc. (NASDAQ:LXEO)Eventide Asset Management LLC lowered its stake in Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) by 44.9% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 1,855,986 shares of the company's stock after selling 1,513,161 shares during the period. Eventide AsNovember 29, 2024 | marketbeat.comPaula H. Cholmondeley Bought 96% More Shares In Lexeo TherapeuticsNovember 28, 2024 | finance.yahoo.comLexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Consensus Recommendation of "Buy" by AnalystsShares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) have been given a consensus rating of "Buy" by the six analysts that are covering the company, MarketBeat reports. Five research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendationNovember 28, 2024 | marketbeat.comLexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Consensus Recommendation of "Buy" from AnalystsShares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) have been given an average rating of "Buy" by the six analysts that are currently covering the company, MarketBeat reports. Five investment analysts have rated the stock with a buy recommendation and one has issued a strong buy reNovember 28, 2024 | marketbeat.comLexeo Therapeutics’ Promising Gene Therapy Progress and Strong Financial Position Present Attractive Investment OpportunityNovember 22, 2024 | markets.businessinsider.comHere's Why We're Watching Lexeo Therapeutics' (NASDAQ:LXEO) Cash Burn SituationNovember 20, 2024 | finance.yahoo.comChardan Capital Brokers Decrease Earnings Estimates for LXEOLexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) - Stock analysts at Chardan Capital reduced their FY2024 EPS estimates for Lexeo Therapeutics in a research report issued on Wednesday, November 13th. Chardan Capital analyst G. Livshits now anticipates that the company will post earnings of ($November 18, 2024 | marketbeat.comWhat is HC Wainwright's Forecast for LXEO FY2024 Earnings?Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) - Stock analysts at HC Wainwright cut their FY2024 earnings per share (EPS) estimates for shares of Lexeo Therapeutics in a research report issued to clients and investors on Thursday, November 14th. HC Wainwright analyst M. Kapoor now forecastNovember 18, 2024 | marketbeat.comEquities Analysts Set Expectations for LXEO FY2024 EarningsLexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) - Leerink Partnrs cut their FY2024 earnings estimates for Lexeo Therapeutics in a research report issued on Wednesday, November 13th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will post earnings of ($3.04) per share fNovember 18, 2024 | marketbeat.comLexeo Therapeutics Advances Cardiac Portfolio Amid Financial ReportNovember 15, 2024 | markets.businessinsider.comLexeo Therapeutics, Inc. (LXEO) Gets a Buy from RBC CapitalNovember 15, 2024 | markets.businessinsider.comPromising Developments in Lexeo Therapeutics’ LX2006 Program Drive Buy RatingNovember 14, 2024 | markets.businessinsider.comLexeo Therapeutics price target raised to $23 from $21 at H.C. WainwrightNovember 14, 2024 | markets.businessinsider.comInsider Selling: Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Sells 2,500 Shares of StockNovember 14, 2024 | insidertrades.comHC Wainwright Increases Lexeo Therapeutics (NASDAQ:LXEO) Price Target to $23.00HC Wainwright raised their target price on Lexeo Therapeutics from $21.00 to $23.00 and gave the company a "buy" rating in a research note on Thursday.November 14, 2024 | marketbeat.comLexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial ResultsNovember 13, 2024 | globenewswire.comLexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Recommendation of "Buy" from AnalystsShares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) have received an average recommendation of "Buy" from the nine research firms that are covering the company, MarketBeat.com reports. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buNovember 3, 2024 | marketbeat.comCautious Optimism for Lexeo Therapeutics’ LX1001: Encouraging Interim Results and Investment PotentialOctober 31, 2024 | markets.businessinsider.comLexeo Therapeutics announces positive results from Phase 1/2 study of LX1001October 31, 2024 | markets.businessinsider.comHC Wainwright Reiterates "Buy" Rating for Lexeo Therapeutics (NASDAQ:LXEO)HC Wainwright reaffirmed a "buy" rating and issued a $21.00 price target on shares of Lexeo Therapeutics in a research note on Thursday.October 31, 2024 | marketbeat.comLexeo Therapeutics Sees Positive Results for Alzheimer's Disease TreatmentOctober 30, 2024 | marketwatch.comLexeo Therapeutics Reports Positive Interim Data From Phase 1/2 Study Of LX1001 In ADOctober 30, 2024 | markets.businessinsider.comLexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer's Disease, at the Clinical Trials on Alzheimer's Disease (CTAD) ConferenceOctober 30, 2024 | globenewswire.comNovo Holdings A S Sells 327,919 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO)Novo Holdings A S lessened its position in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) by 22.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,122,581 shares of the compOctober 27, 2024 | marketbeat.comLexeo Therapeutics' (LXEO) Buy Rating Reiterated at Chardan CapitalChardan Capital reissued a "buy" rating and set a $23.00 price objective on shares of Lexeo Therapeutics in a report on Friday.October 25, 2024 | marketbeat.comLexeo Therapeutics: Promising Alzheimer’s Treatment Advances Drive Buy RatingOctober 25, 2024 | markets.businessinsider.comLexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 ConferenceOctober 22, 2024 | markets.businessinsider.comLexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 ConferenceOctober 22, 2024 | globenewswire.comRichard Nolan Townsend Sells 5,000 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) StockOctober 16, 2024 | insidertrades.comInsider Selling: Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Sells 5,000 Shares of StockLexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) CEO Richard Nolan Townsend sold 5,000 shares of the firm's stock in a transaction that occurred on Thursday, October 10th. The stock was sold at an average price of $8.10, for a total transaction of $40,500.00. Following the transaction, the chief executive officer now owns 120,695 shares in the company, valued at approximately $977,629.50. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.October 15, 2024 | marketbeat.comLexeo Therapeutics, Inc. (LXEO) Receives a Buy from Stifel NicolausOctober 10, 2024 | markets.businessinsider.comLarimar Therapeutics' Friedreich's Ataxia Approach Could Have Considerable Upside PotentialOctober 6, 2024 | seekingalpha.com Get Lexeo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LXEO and its competitors with MarketBeat's FREE daily newsletter. Email Address LXEO Media Mentions By Week LXEO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LXEO News Sentiment▼0.560.63▲Average Medical News Sentiment LXEO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LXEO Articles This Week▼42▲LXEO Articles Average Week Get Lexeo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LXEO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Cogent Biosciences News Today Phibro Animal Health News Today Relay Therapeutics News Today Avid Bioservices News Today Sana Biotechnology News Today Tyra Biosciences News Today Septerna News Today Avadel Pharmaceuticals News Today Immatics News Today Cronos Group News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LXEO) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexeo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexeo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LXEO Stock Alerts